Epitalon (Epithalon): A Pineal-Derived Tetrapeptide for Telomerase and Longevity Research

This content is provided by Superpower Health for educational and informational purposes only. Superpower Health does not prescribe, sell, or facilitate access to Epitalon. Epitalon is not FDA-approved for human use. This page is not a substitute for medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider.

The pineal gland has been associated with longevity in medical literature since at least the 1970s, when Russian researchers began isolating bioactive peptides from bovine pineal extracts and injecting them into aging animals. What came out of that program was not a single molecule but an entire lineage of compounds. Epitalon is a four-amino-acid synthetic peptide with the sequence alanine-glutamic acid-aspartic acid-glycine (AEDG). It is the most studied compound from that lineage. Its proponents describe it as a telomerase activator and lifespan extender. Its critics note that nearly the entire published evidence base comes from a single research group, and that no Western randomized controlled trial has been completed. Both observations are accurate.

This article covers what Epitalon is, where it came from, what the animal and human data actually show, what a 2025 independent replication study means for the telomerase claim, and which biomarkers are conceptually relevant to the questions Epitalon researchers are trying to answer.

Key Takeaways

• Regulatory Status: As of April 2026, Epitalon is not FDA-approved for any indication. It has no DailyMed prescribing information. It is available in the United States only as a research chemical or compounded preparation; it is not approved by any major Western regulatory agency.
• Research Stage: Extensive preclinical animal data (primarily rodent and primate); limited human observational data from Russian cohorts using the pineal extract Epithalamin rather than synthetic Epitalon; two independent in-vitro replications of the telomerase-activation claim published in 2025.
• Availability: Not available through Superpower. Available from research chemical vendors in the United States; quality, purity, and dosing accuracy are not regulated or independently verified.
• What it is: A synthetic tetrapeptide (Ala-Glu-Asp-Gly) that is the active analog of the bovine pineal extract Epithalamin, developed at the St. Petersburg Institute of Bioregulation and Gerontology.
• What the evidence actually shows: Telomerase activation and telomere elongation demonstrated in human fetal fibroblasts (in vitro), with a 2025 independent replication in normal breast epithelial and fibroblast cell lines; rodent lifespan data mixed and regimen-dependent; human evidence limited to observational cohort studies using the parent extract, not synthetic AEDG.
• Authoritative reference: PubChem CID 219042 (Epitalon)

What Is Epitalon and Where Does It Come From?

The Khavinson bioregulator program

Epitalon emerged from a research program that Vladimir Khavinson began in the 1970s at what became the St. Petersburg Institute of Bioregulation and Gerontology. The program's premise was that organs contain short peptide sequences that regulate gene expression in an age-dependent, tissue-specific manner. If aging reflects the progressive decline of these peptide signals, then supplying them exogenously should theoretically slow the decline. The bovine pineal extract Epithalamin was one of the first products of this program. In a foundational 2002 monograph published in Neuroendocrinology Letters and available at PubMed, Khavinson documented the theoretical framework and summarized early animal findings across species including mice, rats, monkeys, and fruit flies.

Isolation of AEDG from the pineal extract

The transition from Epithalamin to synthetic Epitalon required first establishing that AEDG is genuinely present in the bovine pineal complex rather than a purely rational-design analog. That confirmation came formally in a 2017 mass-spectrometry study by Khavinson, Kopylov, Vaskovsky, Ryzhak, and Lin'kova, published in Bulletin of Experimental Biology and Medicine and available at PubMed. HPLC and MS analysis of the pineal polypeptide complex identified AEDG as an actual constituent, not a hypothetical active fragment. This provides structural legitimacy to Epitalon as a simplified analog of the parent extract rather than an entirely synthetic invention.

Current state of the evidence base

A 2025 narrative review by Araj, Brzezik, Mądra-Gackowska, and Szeleszczuk from the Medical University of Warsaw, published in International Journal of Molecular Sciences and available at PubMed, synthesizes 25 years of Epitalon research. The review acknowledges claimed geroprotective, neuroendocrine, antioxidant, antimutagenic, and telomerase-related effects while flagging that physicochemical and structural data remain sparse. It is the most rigorous independent summary of the evidence written outside the Khavinson group.

One structural reality shapes how all Epitalon evidence must be interpreted. The majority of published studies originate from a small cluster of institutions: Khavinson's group at the St. Petersburg Institute; Anisimov's group at the Petrov National Medical Research Centre of Oncology; and the Korkushko-Shatilo collaboration at the Institute of Gerontology in Kyiv. A large fraction of the human data appears in Russian-language journals that were not subject to independent Western peer review. This does not invalidate the findings, but it means independent replication is essential before conclusions can be treated as established.

The Telomerase Claim: What the Evidence Shows

The original in-vitro telomerase findings

The core claim that Epitalon activates telomerase rests on a pair of in-vitro studies from the Khavinson laboratory. A 2003 paper in Bulletin of Experimental Biology and Medicine by Khavinson, Bondarev, and Butyugov reported that Epitalon applied to cultured telomerase-negative human fetal fibroblasts induced expression of the catalytic subunit hTERT, restored detectable telomerase enzymatic activity, and elongated telomeres; the abstract reports only qualitative induction, without fold-change values, confidence intervals, or p-values. A 2004 follow-up in the same journal by Khavinson, Bondarev, Butyugov, and Smirnova, using human fetal pulmonary fibroblasts from a 24-week fetus, reported that Epithalon-treated cultures underwent 44 total passages compared with 34 in untreated controls — that is, approximately 10 additional divisions beyond the point at which control cells arrested — with telomere length restored to a size "comparable to their length during early passages." Exact concentrations, N per condition, and statistical tests were not reported in the abstract. These are the foundational papers for the "overcomes the Hayflick limit in vitro" claim. They are legitimate findings from peer-reviewed journals. They are also small in-vitro studies by a single laboratory that, until 2025, had no independent Western replication.

The 2025 independent Western replication

The evidentiary picture changed in 2025. A 2025 in-vitro study in Biogerontology by Al-Dulaimi, Thomas, and colleagues at Brunel University London, available at PubMed, exposed normal human mammary epithelial cells (HMEC) and IBR.3 fibroblasts to Epitalon at 1 microgram/mL for three weeks and reported dose-dependent telomere length extension via hTERT and telomerase upregulation, while in the 21NT and BT474 breast cancer lines treated at 0.1 to 1 microgram/mL for four days the mechanism differed and Epitalon appeared to act through ALT (alternative lengthening of telomeres) rather than classical telomerase activation. This is the first high-quality independent Western replication of the telomere-elongation claim in normal human cells, and its significance lies precisely in its independence from the Khavinson group. The limitation is equally important: the study is entirely in cell culture, quantitative effect sizes and p-values were not reported in the abstract, and telomere behavior in two-dimensional cell lines does not predict what happens in the tissue-specific microenvironments of a living organism.

A second non-Khavinson replication in a different model

A 2025 study by Ullah, Haider, Perera, Lee, Idrees, Park, and Kong at Gyeongsang National University in South Korea, published in Life Sciences and available at PubMed, examined Epitalon in bovine cumulus-oocyte complexes. Epitalon activated telomerase in these reproductive cells, improved oocyte maturation rate, and enhanced post-thaw blastocyst hatching and implantation potential. This is a second non-Russian replication of the telomerase-activation mechanism, but it uses a reproductive biology model with no direct bearing on human aging biology.

What the telomerase data does not support

Despite the 2025 replications, several claims commonly made about Epitalon are not supported by the available evidence. Telomerase activation in cultured human cells does not establish that Epitalon activates telomerase in vivo in adult human tissues. Fibroblast telomere elongation does not predict lifespan extension. No completed human trial has measured telomere length before and after Epitalon administration in a placebo-controlled design. Describing Epitalon as a compound that "activates telomerase in humans" or "extends telomeres in people" exceeds what the current evidence supports. The more accurate framing is that Epitalon has been shown to activate telomerase in human cell cultures, with independent replication now available from Western laboratories.

Animal Lifespan Data

Female rodent studies: mixed and regimen-dependent results

Two rodent lifespan studies from the Vinogradova, Bukalev, Zabezhinski, Semenchenko, Khavinson, and Anisimov group provide important nuance. A 2007 study in Bulletin of Experimental Biology and Medicine, available at PubMed, examined female rats under three lighting conditions: standard, natural Northwest-Russian light cycle, and constant illumination. Epitalon at 0.1 microgram five times per week did not change lifespan under standard lighting. It extended maximum lifespan by approximately 95 days under natural light and by 24 days under constant illumination. Spontaneous tumor incidence decreased only in the natural-light group. The 2001 mouse study by Anisimov, Khavinson, and colleagues, available at PubMed, reported slower aging and extended lifespan in female CBA mice receiving subcutaneous Epithalon from six months of age, alongside reduced tumor incidence and decelerated free-radical processes. These findings are suggestive but carry the same caveats: they are from the same research group, and the effects depend heavily on experimental conditions.

Male rodent data and the sex-specific pattern

A 2008 companion study by the same group, available at PubMed, examined male rats under the same lighting protocols. Results diverged from the female data: Epitalon did not extend mean lifespan in males but normalized population aging rate under altered light conditions and reduced spontaneous tumor incidence, specifically testicular Leydigomas and leukemias. The contrast between male and female rodent results is not well understood. It underlines that any single summary claim about Epitalon's effects on lifespan misrepresents the actual data, which are conditional, species-specific, sex-specific, and lighting-dependent.

Oncostatic signals in rodent studies

The rodent tumor data deserve separate attention because they represent the most consistent signal across studies. A 2005 study of senescence-accelerated mice by Anisimov, Popovich, Zabezhinski, Rozenfel'd, Khavinson, Semenchenko, and Yashin, published in Voprosy Onkologii and available at PubMed, found that Epitalon extended survival of the last ten percent of SAMP-1 mice without reducing lymphoma incidence. A 2006 collaborative study by Kossoy, Anisimov, Ben-Hur, and Zusman, published in In Vivo and available at PubMed, reported reduced malignant tumor burden and elimination of metastases in Epitalon-treated female C3H/He mice. This is one of the few studies from outside the Khavinson group in the rodent oncology literature. A 2003 review by Anisimov in Critical Reviews in Oncology/Hematology, available at PubMed, places both Epithalamin and Epitalon in the context of pineal-axis mammary carcinogenesis inhibitors alongside melatonin. Rodent oncostatic data are not translatable to human cancer prevention claims.

The Pineal-Melatonin Axis and Circadian Mechanisms

Restoration of nocturnal melatonin secretion

One of the better-documented mechanistic claims for Epitalon is its apparent ability to restore nocturnal melatonin secretion in older organisms with pineal insufficiency. A 2007 study by Korkushko, Lapin, Goncharova, Khavinson, and colleagues, published in Advances in Gerontology and available at PubMed, reported that both Epithalamin and synthetic Epitalon restored the nocturnal peak of melatonin release and normalized circadian melatonin profiles in old rhesus monkeys and in elderly human subjects with documented pineal insufficiency. The study was non-randomized. The finding is consistent with the proposed mechanism that Epitalon's tetrapeptide sequence signals the pineal gland to restore age-related decline in melatonin output.

Circadian gene regulation

A 2020 study by Ivko, Linkova, Ilina, Sharova, and Ryzhak, published in Advances in Gerontology and available at PubMed, examined circadian gene expression in leukocytes of middle-aged subjects with reduced pineal melatonin output. AEDG treatment normalized the overexpression of Clock and Csnk1e and corrected the underexpression of Cry2, while increasing urinary 6-sulfatoxymelatonin excretion by approximately 1.7-fold. These are circadian clock genes whose dysregulation is associated with accelerated aging. The finding is mechanistically interesting but comes from a small Russian study and has not been independently replicated.

Human Observational Data: What Exists and What It Shows

The 266-person elderly cohort study

The most widely cited human longevity claim for Epitalon traces to a 2003 cohort study in Neuroendocrinology Letters by Khavinson and Morozov, available at PubMed, in which 266 elderly persons were followed for six to eight years after receiving bioregulators over the first two to three years. The reported mortality reductions versus controls were 1.6 to 1.8-fold in the Epithalamin-only group, 2.0 to 2.1-fold in the Thymalin-only group, 2.5-fold in the combined Thymalin plus Epithalamin group, and approximately 4.1-fold in patients who received annual combined courses across six years. These numbers are striking, but three features of the study design limit what can be concluded from them: although labeled a clinical trial, it was unblinded and did not include a placebo-controlled arm, with no p-values reported in the abstract; it used the pineal extract Epithalamin rather than synthetic Epitalon; and it has never been independently replicated by a group outside the Khavinson-Korkushko collaboration. A mortality reduction of this magnitude in an unblinded single-center cohort cannot be treated as evidence equivalent to a rigorously randomized, blinded, placebo-controlled trial.

The 12- and 15-year cardiovascular follow-up studies

Two longer-term follow-up studies from the Korkushko, Khavinson, and Shatilo group provide the most extensive human data. A 2006 randomized 12-year clinical follow-up in Bulletin of Experimental Biology and Medicine by Korkushko, Khavinson, Shatilo, and Antonyuk-Shcheglova, available at PubMed, enrolled elderly patients with coronary disease and accelerated cardiovascular aging to receive Epithalamine courses added to standard care and reported 2-fold lower cardiovascular mortality, 2-fold lower incidence of cardiovascular failure and respiratory disease, and 28% lower total mortality versus controls, with increased exercise tolerance and decelerated cardiovascular aging (p-values not reported in the abstract). A 2011 extension to 15 years in the same journal by the same authors, available at PubMed, followed 79 patients (39 treated across six courses over three years versus 40 controls) and reported preserved physical endurance, normalized melatonin circadian rhythm, normalized carbohydrate and lipid metabolism, and significantly lower mortality in the Epithalamin group. These are the strongest human data in the Epitalon/Epithalamin literature. They are also single-center studies using the pineal extract rather than synthetic AEDG, no numerical p-values are provided in the abstracts, and they have not been independently replicated. The distinction between Epithalamin and synthetic Epitalon matters: every human clinical study of meaningful size used the polypeptide complex, not the tetrapeptide analog.

Anti-Inflammatory and Translational Findings

Anti-inflammatory effects in monocytes

A 2022 Italy-Russia collaboration by Avolio, Martinotti, Khavinson, and colleagues, published in International Journal of Molecular Sciences and available at PubMed, examined Epitalon in LPS-stimulated THP-1 human monocytes. The peptide reduced TNF and IL-6 secretion and decreased monocyte adhesion to activated endothelium. This provides a mechanistic signal for anti-inflammatory activity in human immune cells and represents a collaborative study that extends beyond the purely in-house Khavinson output.

Diabetic retinopathy model: most recent translational work

The most recent Epitalon translational study as of April 2026 is a 2025 Italian-Russian collaboration by Gatta, Dovizio, Milillo, Khavinson, Trofimova, and colleagues, published in Stem Cell Reviews and Reports and available at PubMed. In ARPE-19 retinal pigment epithelial cells under high-glucose conditions modeling diabetic retinopathy, Epitalon restored wound healing, reduced reactive oxygen species, and inhibited hyperglycemia-induced epithelial-mesenchymal transition. This is early-stage preclinical work exploring an ophthalmic application, but it extends the mechanistic scope of Epitalon beyond aging and into metabolic disease models.

Safety Considerations and the Unregulated Source Problem

Absence of clinical safety data

No completed, peer-reviewed human safety trial of synthetic Epitalon has been published in Western literature. The animal studies do not report significant adverse events at studied doses, and the Russian observational cohort studies do not document serious harms. The 2025 Warsaw narrative review by Araj and colleagues notes the absence of adequate physicochemical characterization data as a gap in the published record. This means that the safety profile of synthetic Epitalon in humans (including pharmacokinetics, tissue distribution, organ clearance, and immunogenicity) is essentially unstudied in adequately controlled conditions.

Unregulated research chemical market

Epitalon is commercially available in the United States as a research peptide from online vendors. These products are not subject to FDA review for purity, potency, sterility, or accurate labeling. Independent testing of research peptides sold online has documented contamination, incorrect concentrations, and misidentified compounds. Anyone obtaining Epitalon through these channels is using a product whose actual content is unknown. This is not a theoretical risk; it is a documented feature of the unregulated research peptide market.

Which Biomarkers Are Relevant to the Questions Epitalon Research Is Asking?

Epitalon does not have FDA-approved uses, and Superpower does not offer it. The biomarkers below are relevant not as monitoring markers for Epitalon use, but because they address the biological domains Epitalon researchers are investigating. Understanding these markers gives anyone interested in longevity science a concrete, testable picture of where they stand on the axes that Epitalon claims to modulate.

• IGF-1 (Insulin-Like Growth Factor 1): IGF-1 declines with age in a pattern that parallels the decline in growth hormone secretion and is closely associated with the somatotropic axis alterations that Epitalon animal studies describe. Khavinson's work frequently reports IGF-1 normalization as a secondary finding in aging-animal models. Baseline IGF-1 is one of the most informative single biomarkers for biological aging trajectory and is testable through Superpower's IGF-1 blood test.
• High-Sensitivity CRP (hs-CRP): Chronic low-grade inflammation, reflected in hs-CRP, is one of the most consistent correlates of biological aging and age-related disease risk. The anti-inflammatory signals in Epitalon's in-vitro work (TNF, IL-6 reduction) connect to this inflammatory aging pathway. Knowing baseline hs-CRP establishes where a person sits on the inflammaging spectrum independently of any compound.
• Melatonin and circadian rhythm biomarkers: The Epitalon-melatonin axis is the mechanism most consistently reported across the literature. Urinary 6-sulfatoxymelatonin is the standard clinical proxy for nocturnal melatonin output. Sleep architecture and circadian disruption biomarkers described in the Superpower guide to sleep quality and circadian rhythm are directly relevant to the proposed mechanism of Epitalon's pineal action.
• Oxidative stress and antioxidant capacity markers: Epitalon animal studies consistently report deceleration of free-radical processes and reductions in lipid peroxidation. While oxidative stress markers are not routine on standard blood panels, they are measured as part of Superpower's longevity-focused testing. The guide to cellular aging and longevity biomarkers describes the markers most relevant to this domain.
• Hemoglobin A1c (HbA1c) and fasting glucose: The 2025 retinal epithelial cell study places Epitalon in a metabolic disease context for the first time. Baseline metabolic markers including HbA1c, fasting glucose, and insulin are independently important for understanding biological age and long-term disease risk, regardless of interest in any specific compound.

Is Epitalon Legal and How Is It Available?

As of April 2026, Epitalon is not FDA-approved for any indication. It has no approved drug application, no DailyMed prescribing information, and no cleared pathway for human use in the United States. It is not classified as a controlled substance under the Controlled Substances Act, which means possession of research-grade Epitalon is not a federal crime, but it also cannot be legally marketed, sold, or prescribed as a drug.

The legal status of compounded Epitalon in the United States is unsettled. Under Section 503A of the Federal Food, Drug, and Cosmetic Act, a bulk drug substance must appear on FDA's Category 1 permitted list, have a USP or NF monograph, or be a component of an FDA-approved drug to be eligible for compounding; Epitalon meets none of these criteria. It has also not been placed on the Category 2 prohibited list. This leaves it in a regulatory gray zone rather than under a clearly authorized pathway. Providers who prescribe compounded Epitalon do so without a formal FDA-reviewed compounding designation, and patients should understand this context when evaluating any compounded preparation.

Epitalon is also sold widely as a research chemical through online peptide vendors. These products are not subject to FDA oversight for purity or potency. Superpower does not offer Epitalon through its platform.

Testing Your Baseline Before Exploring Longevity Science

The scientific questions Epitalon research is organized around are genuinely interesting: Does telomerase activation in aging tissues slow biological aging? Can pineal peptides restore circadian function in older adults? Do anti-inflammatory tetrapeptides reduce the biological age trajectory in humans? These are questions longevity medicine is actively investigating. What Epitalon does not yet have is the human trial data to answer them definitively.

What is available, right now, is a clear picture of your own biological aging markers. IGF-1, hs-CRP, fasting metabolic markers, and circadian health biomarkers are not hypothetical endpoints from a research protocol. They are measurable today, interpretable by a qualified provider, and actionable regardless of whether any particular compound is in your future. Superpower is built on the principle that objective data should precede every health decision. The approach to preventive health that Superpower describes starts with knowing your biology before anything else. That principle applies as much to longevity science as it does to any other domain of health.

IMPORTANT SAFETY INFORMATION

Epitalon (Ala-Glu-Asp-Gly) is not FDA-approved for any indication. No New Drug Application or Investigational New Drug application has been filed for Epitalon in the United States, and no DailyMed prescribing information exists. Epitalon is not listed as a Category 1 (permitted) bulk drug substance on the FDA's 503A list, and it has not been placed on the Category 2 (prohibited) list; its compounding status is unsettled. Superpower is a technology platform; Superpower does not prescribe, sell, compound, or facilitate access to Epitalon.

Do not use Epitalon if you: have an active or suspected malignancy (telomerase activation is a theoretical concern for tumor biology); are pregnant, may become pregnant, or are breastfeeding (no safety data exist for these populations); are a minor (no pediatric safety data); or have a known hypersensitivity to any peptide-based injectable formulation.

Warnings: Products sold online as Epitalon are marketed as research chemicals and are not subject to FDA oversight for identity, purity, sterility, or potency; independent testing of unregulated peptide vendors has documented contamination, incorrect dosing, and misidentified compounds. No published human clinical safety database exists for Epitalon; the adverse event profile in humans has not been characterized through controlled trials. The theoretical mechanism (telomerase activation) has unknown long-term consequences for cell proliferation, including in tissues with malignant or pre-malignant changes.

Common side effects: Not established. Because there are no adequately powered human safety trials, any adverse event profile must be considered unknown.

WADA status: Epitalon is not specifically listed on the World Anti-Doping Agency 2026 Prohibited List, but it may fall under the S0 category (non-approved substances prohibited at all times). Athletes subject to anti-doping controls should confirm current status with their governing body before any use.

Long-term data limitations: The human evidence base consists primarily of reports from a single Russian research group (St. Petersburg Institute of Bioregulation and Gerontology); independent replication by groups outside that program is limited. No Phase 2 or Phase 3 controlled efficacy trial has been completed or published in a peer-reviewed journal indexed in PubMed as of April 2026.

Compound reference: PubChem CID 219042. No FDA-approved prescribing information exists for Epitalon; see dailymed.nlm.nih.gov for labeling of FDA-approved peptide products.

Additional Questions

Are there side effects associated with Epitalon?

No clinical safety trials of synthetic Epitalon in humans have been completed and published in peer-reviewed Western literature. The Russian observational cohort studies and animal studies do not document significant adverse events at the doses studied. The absence of reported harms does not establish safety; it reflects the absence of adequately controlled human safety data. The long-term effects of Epitalon administration in humans, including effects on cell proliferation and oncogenesis given its telomerase-activating mechanism, have not been systematically studied.

What biomarkers should I track if I am interested in longevity science?

The biological domains most relevant to Epitalon's proposed mechanisms are IGF-1 (somatotropic axis and biological aging), high-sensitivity CRP (inflammatory aging), fasting glucose and HbA1c (metabolic aging), and circadian health indicators. These markers are measurable now through standard blood panels and provide a concrete biological baseline independent of any compound. A qualified provider can interpret these values in the context of your age, health history, and goals.

How does Epitalon compare to other longevity peptides?

Epitalon has one of the most extensive published evidence bases among research-only longevity peptides, though that evidence base is heavily concentrated within a single Russian research network. MOTS-c, humanin, and related mitochondrial-derived peptides have a different mechanism of action and a more distributed international research base. None of these compounds has completed a large-scale randomized controlled trial in humans demonstrating lifespan extension or reliable biological aging reversal. Comparing them based on current evidence would require treating animal and small in-vitro data as clinically equivalent, which they are not.